Korean J Ophthalmol.  2007 Dec;21(4):213-215. 10.3341/kjo.2007.21.4.213.

Retinal Angiomatous Proliferation and Intravitreal Bevacizumab Injection

• Kang JH
• Park KA
• Chung SE
• Kang SW

• KMID: 754638
• DOI: http://doi.org/10.3341/kjo.2007.21.4.213

Abstract

PURPOSE: To evaluate the short-term efficacy and safety of intravitreal bevacizumab injection (IVBI) in patients with retinal angiomatous proliferation (RAP). METHODS: Seven eyes of 5 patients with RAP were included in this study. All of the eyes evidenced stage 2 RAP lesions, except for one eye with a stage 3 lesion. IVBI (1.25 mg/0.05 cc) were conducted at 4 or 6-week intervals. Complete ocular examinations, angiographic results and optical coherence tomographic findings before and after the IVBI were analyzed at baseline and upon the follow-up visits. RESULTS: Seven eyes were studied in 5 patients who had undergone IVBI. Partial (3 eyes) or complete (4 eyes) regression of RAP was noted after IVBI in all of the studied eyes. Visual acuity improved in 5 of the eyes, and was stable in 2 of the eyes. One eye evidenced severe intraocular inflammation after IVBI and a subsequent development of new RAP, which was controlled with vitrectomy and repeat IVBI. CONCLUSIONS: This treatment was effective over 6 months, stabilizing or improving visual acuity and reducing angiographic leakage. These short-term results suggest that IVBI may constitute a promising therapeutic option, particularly in the early stages of RAP.

Keyword

Intravitreal bevacizumab injection; Retinal angiomatous proliferation

MeSH Terms

Aged
Aged, 80 and over
Angiogenesis Inhibitors/*administration & dosage
Antibodies, Monoclonal/*administration & dosage
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Injections
Male
Middle Aged
Retinal Neovascularization/complications/*drug therapy/pathology
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Vitreoretinopathy, Proliferative/complications/*drug therapy/pathology
Vitreous Body

Figure

• 

  Fig. 1 Early and late phase indocyanine green angiogram (ICGA) of the right eye of the patient #2 shows focal area of hyperfluorescence and discrete rim of hypofluorescence due to retinal pigment epithelial detachment before treatment (A, B). At 5 months after intravitreal bevacizumab injection (C, D) it shows partial ablation of lesion on ICGA.

Reference

1. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001. 21:416–434.

2. Gass JD, Agarwal A, Lavina AM, Tawansy KA. Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis. Retina. 2003. 23:741–751.

3. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology. 1996. 103:2042–2053.

4. Kuhn D, Meunier I, Soubrane G, Coscas G. Imaging of chorioretinal anastomoses in vascularized retinal pigment epithelium detachments. Arch Ophthalmol. 1995. 113:1392–1398.

5. Blodi CF, Russell SR, Pulido JS, Folk JC. Direct and feeder vessel photocoagulation of retinal angiomas with dye yellow laser. Ophthalmology. 1990. 97:791–795.

6. Borrillo JL, Sivalingam A, Martidis A, Federman JL. Surgical ablation of retinal angiomatous proliferation. Arch Ophthalmol. 2003. 121:558–561.

7. Boscia F, Furino C, Prascina F, et al. Combined surgical ablation and intravitreal triamcinolone acetonide for retinal angiomatous proliferation. Eur J Ophthalmol. 2005. 15:513–516.

8. Boscia F, Parodi MB, Furino C, et al. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2006. 244:1224–1232.

9. Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol. 2005. 123:1644–1650.

10. Kuroiwa S, Arai J, Gaun S, et al. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. Retina. 2003. 23:417–420.

11. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol. 1997. 151:281–291.

12. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996. 37:855–868.

13. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol. 1996. 80:363–366.